The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

Dermatologic TherapyVolume 33, Issue 6 e14192 ORIGINAL ARTICLE The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria Ozlem Su, Ozlem Su orcid.org/0000-0002-1140-9261 Department of Dermatoveneorology, Bezmialem Vakif University, Istanbul, TurkeySearch for more papers by this authorAnil Gulsel Bahali, Corresponding Author Anil Gulsel Bahali [email protected] orcid.org/0000-0002-8124-1230 Department of Dermatoveneorology, Bezmialem Vakif University, Istanbul, Turkey Correspondence Anil Gulsel Bahali, Bezmialem Vakif University, Department of Dermatology, 34710 Istanbul, Turkey. Email: [email protected]Search for more papers by this authorNahide Onsun, Nahide Onsun orcid.org/0000-0001-6259-0219 Department of Dermatoveneorology, Bezmialem Vakif University, Istanbul, TurkeySearch for more papers by this author Ozlem Su, Ozlem Su orcid.org/0000-0002-1140-9261 Department of Dermatoveneorology, Bezmialem Vakif University, Istanbul, TurkeySearch for more papers by this authorAnil Gulsel Bahali, Corresponding Author Anil Gulsel Bahali [email protected] orcid.org/0000-0002-8124-1230 Department of Dermatoveneorology, Bezmialem Vakif University, Istanbul, Turkey Correspondence Anil Gulsel Bahali, Bezmialem Vakif University, Department of Dermatology, 34710 Istanbul, Turkey. Email: [email protected]Search for more papers by this authorNahide Onsun, Nahide Onsun orcid.org/0000-0001-6259-0219 Department of Dermatoveneorology, Bezmialem Vakif University, Istanbul, TurkeySearch for more papers by this author First published: 13 August 2020 https://doi.org/10.1111/dth.14192Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract It is known that omalizumab (OMA) is an effective and safe treatment option in the treatment of chronic spontaneous urticaria (CSU). In the literature, there are vary studies about effect of OMA treatment in CSU such as different response rates to treatment, different dose / time regime and different relapse rates after treatment. To investigate the evaluate the effect of at least 1 year continuous OMA treatment on relapse in CSU patients. Fifty patients were included in this study. There was a significant decreased between UAS7 score before and after OMA treatment. There was no significant difference between the sixth and 12th month after OMA for UAS 7 scores. At the end of 12 month,84% of patients had complete or good response to OMA treatment. Twenty-three of 34 patients (67.6%) who discontinued treatment had relapse and 11 patients had no relapse. Duration of disease was significantly higher in patients who had relapse. Based on our study result we suggest that long disease duration may increase the risk of relapse. Although it is not statistically significant, without interruption OMA treatment for more than 1 year may decrease relapse risk in patients who respond well to the therapy. CONFLICT OF INTEREST The authors declare no potential conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are openly available in [repository name e.g "figshare"] at http://doi.org/[doi], reference number [reference number]. Citing Literature Volume33, Issue6November/December 2020e14192 RelatedInformation